LANTUS® is the only 24-hour insulin approved exclusively for use once a day1
From Lepore et al2 and LANTUS® Prescribing Information1.
A double-blind, randomized, crossover euglycemic clamp study involving 20 patients with type 1 diabetes.
*Between-patient variability (coefficient of variation): insulin glargine, 84%;
NPH insulin, 78%.
†Glucose utilization rate (mg/kg/min), determined as the amount of glucose
infused to maintain constant plasma glucose levels (hourly mean values); indicative
of insulin activity.
It's vital to recognize the time-action profiles of different basal insulins
Action profiles of detemir and NPH in type 1 diabetes patients
‡AUCGIR=419 mg/kg; GIRmax=1.1 mg/kg/min.
§AUCGIR=1184 mg/kg; GIRmax=1.7 mg/kg/min.
¶AUCGIR=743 mg/kg; GIRmax=1.6 mg/kg/min.
From Levemir® Prescribing Information.17
- Detemir can be administered once or twice daily17
- Mean duration of action of detemir ranged from 5.7 hours at lowest dose to 23.2
hours at highest dose (sampling period: 24 hours)17
Action profiles of LANTUS® and detemir in type 1 diabetes patients
From Porcellati et al.22
A randomized, double-blind crossover study of 24 subjects with type 1 diabetes naïve to glargine and detemir. PG clamped at 100 mg/dL for 24 hours after subcutaneous injection of 0.35 U/kg of either glargine or detemir.
24-hour duration of action that provides convenient once-daily insulin therapy
LANTUS®, long-acting (basal) insulin, provides:
- Once-daily dosing1
compared to NPH insulin twice daily injections for 24-hour glucose lowering
- Predictable duration of action
- Demonstrated low rate of hypoglycemia1
IMPORTANT SAFETY INFORMATION FOR LANTUS®
LANTUS® is indicated for once-daily subcutaneous administration, at the same
time each day, for the treatment of adult and pediatric patients (6 years and older)
with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who
require basal (long-acting) insulin for the control of hyperglycemia.
LANTUS® SoloSTAR® is a disposable prefilled insulin pen. Needles and the Lantus® SoloSTAR® pen must not be shared.
LANTUS® MUST NOT BE DILUTED OR MIXED WITH ANY OTHER INSULIN OR SOLUTION. If mixed
or diluted, the solution may become cloudy, and the onset of action/time to peak
effect may be altered in an unpredictable manner.
LANTUS® is contraindicated in patients hypersensitive to insulin glargine or
the excipients.
Hypoglycemia is the most common adverse effect of insulin, including LANTUS®.
As with all insulins, the timing of hypoglycemia may differ among various insulin
formulations. Glucose monitoring is recommended for all patients with diabetes.
Any change of insulin type and/or regimen should be made cautiously and only under
medical supervision. Concomitant oral antidiabetes treatment may need to be adjusted.
Other adverse events commonly associated with LANTUS® include the following:
lipodystrophy, skin reactions (such as injection-site reaction, pruritus, rash),
and allergic reactions.
In clinical studies in adult patients there was a higher incidence of treatment-emergent
injection-site pain (2.7% LANTUS® vs 0.7% NPH). The reports of pain at the injection
site were usually mild and did not result in discontinuation of therapy.
Please click here for full prescribing information.
